Ikeda, S.; Araki, K.; Kitagawa, M.; Makihara, N.; Nagata, Y.; Fujii, K.; Yoshida, K.; Ikoma, T.; Nakahama, K.; Takeyasu, Y.;
et al. Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology. Cancers 2026, 18, 272.
https://doi.org/10.3390/cancers18020272
AMA Style
Ikeda S, Araki K, Kitagawa M, Makihara N, Nagata Y, Fujii K, Yoshida K, Ikoma T, Nakahama K, Takeyasu Y,
et al. Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology. Cancers. 2026; 18(2):272.
https://doi.org/10.3390/cancers18020272
Chicago/Turabian Style
Ikeda, Satoshi, Keigo Araki, Mai Kitagawa, Natsuno Makihara, Yutaro Nagata, Kazuki Fujii, Kiyori Yoshida, Tatsuki Ikoma, Kahori Nakahama, Yuki Takeyasu,
and et al. 2026. "Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology" Cancers 18, no. 2: 272.
https://doi.org/10.3390/cancers18020272
APA Style
Ikeda, S., Araki, K., Kitagawa, M., Makihara, N., Nagata, Y., Fujii, K., Yoshida, K., Ikoma, T., Nakahama, K., Takeyasu, Y., Katsushima, U., Yamanaka, Y., & Kurata, T.
(2026). Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology. Cancers, 18(2), 272.
https://doi.org/10.3390/cancers18020272
